18F-FLUC PET/MR in Patients With Brain Mets
Recruiting · Phase 3 · NCT06159335
Conditions: Brain Metastasis, Radiation Therapy, Immunotherapy, Active
At a glance
- Research payments reported, 2025
- $20,666
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- University of Wisconsin, Madison (with Blue Earth Diagnostics)
- Tested
- F-Fluciclovine radiotracer (radiation)
- Dates
- Started 2024-01-10; completion 2027-06
- Results posted
- Not yet
The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $20,666 in research payments for this study in 2025 (4 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Wisconsin $20,666
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.